Evidence map›Paper›PMID 28883722›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2017

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.

Henrik Watz, Thierry Troosters, Kai M Beeh, Judith Garcia-Aymerich, Pierluigi Paggiaro, Eduard Molins, Massimo Notari, Antonio Zapata, Diana Jarreta, Esther Garcia Gil

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02424344 (A Multiple Dose, Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Assess the Effect of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combination on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02424344 phase4completednot on this map

A Multiple Dose, Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Assess the Effect of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combination on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorAstraZenecaRan2015 to 2016Enrolled267ConditionsPulmonary Disease, Chronic ObstructiveArmsAclidinium/Formoterol, Placebo
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.International journal of chronic obstructive pulmonary disease · 2018
    Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Henrik WatzPulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Thierry TroostersDepartment of Rehabilitation Sciences, Pulmonary Rehabilitation and Respiratory Division, University Hospital Leuven, KU Leuven, Leuven, Belgium.
Kai M Beehinsaf Respiratory Research Institute GmbH, Wiesbaden, Germany.
Judith Garcia-AymerichBarcelona Institute of Global Health (ISGlobal), Barcelona, Spain.
Pierluigi PaggiaroDepartment of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy.
Eduard MolinsAstraZeneca PLC, Barcelona, Spain.
Massimo NotariA. Menarini Farmaceutica Internazionale S.R.L., Firenze, Italy.
Antonio ZapataLaboratorios Menarini, S.A., Badalona, Spain.
Diana JarretaAstraZeneca PLC, Barcelona, Spain.
Esther Garcia GilAstraZeneca PLC, Barcelona, Spain.
AstraZeneca (Spain) · ESGerman Center for Lung Research · DEKU Leuven · BERespiratory Research Institute · DEUniversitat Pompeu Fabra · ESUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 μg twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the Genuair™/Pressair

Indexed as

ExerciseAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsCanadaDouble-Blind MethodDrug CombinationsEuropeExercise ToleranceFemaleFormoterol FumarateFunctional Residual CapacityHumansInspiratory CapacityLungMaleaclidinium bromideAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsFormoterol FumarateMuscarinic AntagonistsTropanesaclidiniumCOPDexercise capacityformoterolhyperinflationphysical activity

Identifiers

PMID28883722
PMCPMC5574699
OpenAlexW2750520206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.